HDL Composition, Heart Failure, and Its Comorbidities

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Heart Failure Pathophysiology

Background:

• Historically, high-density lipoprotein (HDL) research centered on atherosclerotic coronary disease.
• Emerging evidence suggests HDL biology has untapped potential for heart failure (HF) treatment.
• HF is a complex syndrome involving comorbidities and intricate lipoprotein interactions.

Purpose of the Study:

• To review the impact of heart failure and comorbidities on HDL.
• To explore the cardioprotective properties of HDL in heart failure.
• To identify novel HDL therapeutic targets for heart failure.

Main Methods:

• Literature review focusing on HDL biology and heart failure.
• Analysis of HDL's antioxidant, anti-inflammatory, and endothelial protective functions.
• Examination of HDL-associated proteins (e.g., apolipoprotein A-I, M) and their myocardial effects.

Main Results:

• HDL possesses antioxidant, anti-inflammatory, and endothelial protective properties relevant to HF pathogenesis.
• HDL-associated proteins may exert therapeutic effects on the myocardium.
• Complex interactions exist between HF, comorbidities, and lipoprotein homeostasis.

Conclusions:

• HDL biology offers promising therapeutic avenues for heart failure.
• Targeting HDL and its associated proteins could represent a novel strategy for HF treatment.
• Further research is warranted to elucidate HDL's role and therapeutic potential in heart failure.